Related Experiment Video
Updated: May 1, 2026

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
Published on: June 17, 2013
Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphisms
David A Ziegler1, Paymon Ashourian, Julien S Wonderlick
1Department of Neurology and the Center for Integrative Neuroscience, University of California, San Francisco, San Francisco, CA, USA; Department of Brain & Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.
Genetic variations in the COMT gene increase motor impulsivity in Parkinson disease (PD) patients undergoing dopamine replacement therapy. DRD2 gene variations did not show a significant link to impulsivity in PD patients.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Parkinson disease (PD) is a neurodegenerative disorder affecting motor, cognitive, and psychiatric functions.
- Dopaminergic medications, while crucial for motor symptom management in PD, can lead to side effects like hallucinations and impulse control disorders.
- Individual genetic differences in the dopamine system may influence patient response to dopaminergic therapy.
Purpose of the Study:
- To investigate the hypothesis that specific genetic variations (alleles) influencing dopamine signaling increase motor impulsivity in PD patients on dopamine replacement therapy.
- To examine the relationship between inhibitory control, measured by the Stop Signal Task, and polymorphisms in the COMT Val158Met and DRD2 C957T genes in idiopathic PD patients.
Main Methods:
- Assessed inhibitory ability using the Stop Signal Task in patients with idiopathic Parkinson disease.
- Genotyped patients for COMT Val158Met and DRD2 C957T polymorphisms.
- Correlated genetic variations with performance on the Stop Signal Task to measure motor impulsivity.
Main Results:
- Carriers of the COMT Val/Met and Met/Met genotypes exhibited significantly higher impulsivity on the Stop Signal Task compared to Val/Val carriers.
- No significant association was found between DRD2 C957T polymorphisms and inhibitory ability in PD patients.
- The Met allele of COMT was linked to increased risk of behavioral impulsivity in PD patients receiving dopaminergic therapy.
Conclusions:
- The COMT Val158Met polymorphism, specifically the Met allele, is associated with increased motor impulsivity in Parkinson disease patients treated with dopamine replacement therapy.
- DRD2 polymorphisms appear to play a less significant role in mediating medication-induced motor impulsivity in PD.
- These findings highlight the role of genetic factors in predicting adverse behavioral effects of dopaminergic treatment in PD.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Parkinson's Disease: Overview
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Alterations in Muscle Tone lll

